Sophia Genetics and Devyser, pioneer in diagnostic kits for complex DNA testing, announce the signing of a new partnership to simplify the adoption of Next-Generation DNA Sequencing for routine diagnostic laboratories. Under the terms of the agreement, Sophia Genetics’ advanced analytical platform, Sophia DDM, will support Devyser’s NGS diagnostic kits for hereditary breast cancer and cystic fibrosis.
Sophia Genetics’ and Devyser’s joint effort will immediately be launched worldwide to help routine diagnostic laboratories transition to NGS and obtain improved throughput, reduced hands-on time and trusted results. The solutions will be available through Devyser’s distribution network and to the more than 170 member hospitals of the Sophia DDM clinical genomics community.
Ulf Klangby, CEO and co-founder of Devyser, says, “We are very excited to offer NGS technology that has the capacity to revolutionize genetic testing. This solution will relieve laboratories from the burden of labor-intensive and complex workflows so that they can really focus on diagnostics. Our partnership will help continue to reduce the diagnostic turnaround time from days to hours, enabling laboratories to significantly improve their efficiency and cut costs.”
Jurgi Camblong, CEO and founder of Sophia Genetics, comments, “We are very pleased to broaden the choice of NGS kits supported by Sophia DDM. Our fast-growing clinical genomics community will be able to leverage Devyser’s reliable and easy-to-use products to obtain clinical grade results on Sophia DDM. This partnership continues to help laboratories unlock the power of NGS with record-low turnaround time, improving both diagnostics and treatment options for patients.”
(Press release)
Please login or sign up to comment.
Commenting guidelines